Herpes viruses infecting the retina manifest themselves differently depending upon the interaction between the virus and the host immune system. Most of them are known as necrotizing retinopathies, but nonnecrotizing forms should also be considered in atypical cases of chronic posterior uveitis.
Necrotizing retinopathies are by far the most frequent clinical picture, with a spectrum of severity ranging from the acute retinal necrosis syndrome (almost always seen in healthy individuals) to the progressive outer retinal necrosis syndrome, (PORN), and cytomegalovirus (CMV) retinitis, both of which mainly affect severely immunocompromised patients.
Nonnecrotizing herpetic retinopathies are less frequent and have a number of different manifestations, including vitritis, occlusive vasculitis, papillitis, or macular edema.
ACUTE RETINAL NECROSIS SYNDROME
Acute retinal necrosis (ARN) syndrome is characterized by peripheral necrotizing retinitis, retinal vasculitis, a prominent inflammatory reaction in the vitreous, and a granulomatous anterior uveitis.
Epidemiology and Etiology
ARN is a rare disease, occurring in 1 per 1.6 to 2.0 million people per year in Western countries.
In most cases, ARN is caused by varicella zoster virus (VZV); however, herpes simplex viruses 1 (HSV-1) and 2 (HSV-2) also cause ARN.
HSV-2 is more prevalent in children and adolescents, while HSV-1 mainly occurs in young adults. VZV is usually found in the elderly.
Acute, painless visual loss with floaters
65% of cases are unilateral at presentation; 33% of cases are bilateral (BARN, bilateral acute retinal necrosis)
Conjunctival and ciliary injection of varying intensity
Anterior granulomatous uveitis, which rarely can be associated with hypopyon or hyphema
Patchy or confluent areas of white or cream-colored retinal necrosis initially affecting the peripheral retina and then extending centripetally
Papillitis of varied intensity
Immunocompetent, otherwise healthy young or middle-aged patients, with or without a remote history of herpes virus infection or herpetic encephalitis (an established risk factor for ARN)
ARN is a medical emergency. It is rapidly progressive and second eye involvement will naturally occur in almost 70% of patients in the absence of treatment. More than 50% of patients develop a rhegmatogenous retinal detachment (RRD) due to retinal atrophy secondary to necrosis and vitreous contraction.
ARN needs to be differentiated from other nonviral necrotizing retinopathies, infectious or not (Table 9-1):
Extensive Toxoplasma retino- choroidopathy
Fungal endogenous endophthalmitis
Primary intraocular lymphoma (PIOL)
Retinitis associated with Behçet’s disease
CMV retinitis (occurs only in severely immunocompromised patients)
ARN is primarily a clinical diagnosis.
Because the natural disease course is usually devastating, ancillary tests confirm the etiology and/or eliminate nonviral causes, but they should never cause a delay in empirical treatment.
Two different assays are performed in ocular samples (aqueous humor or vitreous):
Polymerase chain reaction (PCR) for direct detection of viral DNA is highly sensitive with 80% to 96% positivity in both immunocompetent and immunocompromised hosts.
Indirect detection of antibodies directed against virus proteins has 50% to 70% positivity in immunocompetent patients.
In cases of suspected meningitis, a brain MRI and a lumbar puncture should be performed without delay as simultaneous herpetic meningitis or encephalitis is possible.
The primary treatment is medical. Traditionally, this has been administered in an inpatient setting during the acute phase; however, outpatient management has been reported recently but remains somewhat controversial.
The primary treatment is antiviral therapy, which is used to control viral replication and to reduce the risk of bilateralization. Intravitreal injections can be used in cases that are imminently threatening the macula or optic nerve.
Anti-inflammatory therapy is used to minimize the deleterious effects associated with inflammation. Viral replication must be controlled with antiviral medications before administration of systemic corticosteroids.
Antithrombotic therapy should be considered in order to reduce vascular complications.
Laser retinopexy may reduce the occurrence of a RRD, but its efficacy remains controversial.
Patients with vitreous hemorrhage secondary to retinal neovascularization or for RRD should have pars plana vitrectomy, with or without silicone oil tamponade. Early vitrectomy with intravitreal injection of antiviral medications and laser retinopexy can be performed to prevent RRD, although no improvement in final visual acuity has been reported.
Treatment medications are outlined in Table 9-2.
Despite early recognition and institution of prompt therapy, the final visual outcome is generally poor.
RRD and ischemic optic neuropathy (with subsequent optic nerve atrophy) preclude good final visual acuity.
Aizman A, Johnson MW, Elner SG. Treatment of acute retinal necrosis syndrome with oral antiviral medications. Ophthalmology. 2007;114:307–312.
Balansard B, Bodaghi B, Cassoux N, et al. Necrotizing retinopathies simulating acute retinal necrosis syndrome. Br J Ophthalmol. 2005;89(1):96–101.
Ganatra JB, Chandler D, Santos C, et al. Viral causes of the acute retinal necrosis syndrome. Am J Ophthalmol. 2000;129(2):166–172.
Holland, GN. Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive Committee of the American Uveitis Society. Am J Ophthalmol. 1994;117(5):663–667.
Tibbetts MD, Shah CP, Young LH, et al. Treatment of acute retinal necrosis. Ophthalmology. 2010;117(4):818–824.
Wong R, Pavesio CE, Laidlaw DA, et al. Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome. Ophthalmology. 2010;117(3):556–560.
|Antivirals||Acyclovir||10 mg/kg/8 h (1500 mg/m2) IV or|
|800 mg PO 5 times/day|
|Foscarnet||90 mg/kg/12 h IV or/and intravitreal injections|
|Ganciclovir||5 mg/kg/12 h IV or/and intravitreal injections|
|Valganciclovir||900 mg/day b.i.d.|
|Anti-inflammatory drugs||Methylprednisolone||500 mg daily IV for 3 days|
|Prednisone||0.5–1 mg/kg/day with a gradual taper|
|Antithrombotic drugs||Standard heparin|
|Aspirin (acetylsalicylic acid)||100 mg/day|
PROGRESSIVE OUTER RETINAL NECROSIS
Progressive outer retinal necrosis (PORN) is the major form of necrotizing herpetic retinitis affecting immunocompromised patients. Early diagnosis and aggressive antiviral therapy is mandatory, but the visual prognosis generally remains poor.
Epidemiology and Etiology
PORN is the most severe clinical form of herpetic retinitis. Although it appears to affect the outer retina, all retinal layers can become involved.
VZV is the most common agent identified in patients with PORN, but a few cases of HSV-1–associated PORN have been described.
Patients are usually deeply immunocompromised. Most of them suffer from AIDS; however, it has also been described in patients who have had bone marrow transplantation and also those treated with high-dose systemic corticosteroids.
PORN represents an ophthalmologic and medical emergency, as it usually is bilateral and progresses rapidly, and CNS involvement is possible. PORN usually has a poor visual outcome.
Painless decrease of visual acuity
Abrupt loss of central vision in those cases with initial macular involvement
Constriction of visual fields
Multifocal, poorly demarcated, deep retinal opacities of various sizes, without granular borders, scattered throughout the posterior pole and the midperipheral retina. The retinitis spreads outwardly and peripherally, becoming confluent within a few days.
Retinal vasculitis and optic neuritis occur in less than 20% of cases.
The aqueous humor and the vitreous have minimal to no inflammation.
Extremely rapid progression to total retinal necrosis over the course of a few days.
The disease is bilateral at presentation in 70% of cases, and 80% will become bilateral within the first month.
There is a history of recent or ongoing VZV infection in 75% of cases.
CMV retinitis remains the most common opportunistic infection in AIDS, but the clinical picture and course is very different and it usually does not represent a diagnostic dilemma.
ARN syndrome is also a diagnosis to exclude. ARN occurs in otherwise healthy patients, affects the retinal vasculature, and is associated with vitritis (Table 9-3).
Toxoplasma retinochoroiditis when affecting the elderly or immunosuppressed hosts may also produce a similar clinical picture.
The classic clinical picture should suggest the diagnosis and prompt empirical treatment should be administered before ancillary tests are performed.
Aqueous humor PCR should be performed for viral DNA identification and antibody production in order to confirm the pathogenic agent and eliminate other nonviral etiologies.
Brain MRI and lumbar puncture should be performed in every case of PORN, because extremely immunosuppressed patients have an increased risk of encephalitis.
Treatment (Table 9-4)
Patients with PORN must be treated in an inpatient setting.
|Host immune status||Immunocompetent or immunocompromised||Immunocompromised, mainly AIDS|
|Etiologic agent||VZV, HSV-1, HSV-2||Mainly VZV|
|Intraocular inflammation (KPs, AC cells, vitritis)||Present and very important||Rare|
|Bilaterality||25% at presentation||70% at presentation|
|Progression||Centripetally from peripheral foci of retinal necrosis to posterior pole||Centrifugally with rapid confluence|
Combined IV and intravitreal treatment with ganciclovir and foscarnet is the strategy of choice, as IV acyclovir does not treat PORN effectively.
IV corticosteroids must be avoided in nearly all cases.
Acetylsalicylic acid (100 mg per day) can be used to decrease platelet hyperaggregation that occurs in herpetic retinitis.
Prophylactic argon laser retinopexy delimitating necrotic retinal areas can be applied in an effort to reduce the high risk of RRD, although studies are inconclusive about its advantages.
Once RRD has occurred, vitrectomy with silicone oil tamponade is the management of choice. Some authors advocate performing early vitrectomy with intravitreal acyclovir lavage and laser demarcation to prevent RRD, although this has not led to an improvement in final visual acuity.
Patients should be tested for comorbid conditions, such as AIDS. If HIV is found, highly active antiretroviral therapy (HAART) should be promptly instituted.
Despite aggressive treatment, the prognosis is extremely poor. The final visual outcome is no light perception in almost 60% of eyes, mainly related to total retinal necrosis and RRD.
|Active Drug||Dose and Route of Administration||Toxicity|
|Ganciclovir||5 mg/kg IV b.i.d. for 3 weeks, then 5 mg/kg daily IVT injections: 1–2 mg/0.05 mL||Blood cells and liver|
|Foscarnet||180 mg/kg/day IV divided into 2–3 infusions for 3 weeks, then 90–120 mg/kg/day IVT injections: 1.2–2.4 mg/0.05 mL||Renal failure|
|Valgancyclovir||900 mg/day PO, after IV induction phase, as a maintenance regimen||Blood cells and liver|
|Valacyclovir||1 g PO t.i.d. as maintenance treatment||Renal failure|
Ischemic optic neuropathy with further optic atrophy also precludes good visual restoration.
Benz MS, Glaser JS, Davis JL. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol. 2003;135(4):551–553.
Chau Tran TH, et al. Successful treatment with combination of systemic antiviral drugs and intravitreal ganciclovir injections in the management of severe necrotizing herpetic retinitis. Ocul Immunol Inflamm. 2003;11(2):141–144.
Engstrom RE, Jr., et al. The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology. 1994;101(9):1488–1502.
Forster DJ, et al. Rapidly progressive outer retinal necrosis in the acquired immunodeficiency syndrome. Am J Ophthalmol. 1990;110(4):341–348.
Moorthy RS, et al. Management of varicella zoster virus retinitis in AIDS. Br J Ophthalmol. 1997;81(3):189–194.
CONGENITAL RUBELLA SYNDROME
Rubella is a mild systemic viral illness transmitted by respiratory droplets, and has an incubation period of 2 weeks. When a pregnant woman gets infected for the first time, the virus is transmitted transplacentally and it can lead to miscarriage, stillbirth, or to an infant with multiple systemic abnormalities. The range of congenital defects differs according to the gestational age of the child and the earlier in gestation that the infection occurs, the worse the damage; infection during the first 12 weeks usually results in cardiac and ocular involvement, while infection during the 12th to 28th weeks results in deafness and pulmonary artery stenosis. The consequences of rubella infection in utero are collectively termed congenital rubella syndrome (CRS).
Etiology and Epidemiology
Rubella is a single-stranded RNA virus and humans are the only host. The World Health Organization estimates that more than 100,000 children are born with CRS each year worldwide, most of them in developing countries.
Vaccination tremendously reduces the occurrence of CRS.
The symptoms depend on the organ systems involved and on the severity of damage. Parents often note leukocoria.
Signs (Figs. 9-10 to 9-16)
Patent ductus arteriosus
Pulmonary artery stenosis
Atrial and ventricular septal defects
The most common finding is progressive sensorineural deafness, which occurs in 44% of cases.
Vestibular function is rarely impaired.
Moderate to severe mental retardation
Schizophrenia-like clinical picture
Intrauterine growth retardation
Failure to thrive
Insulin-dependent diabetes mellitus
Cataract (usually bilateral, occasionally unilateral) occurs in the majority of patients.
Salt and pepper retinopathy: occurs in approximately 20% of patients. The appearance ranges from a fine stippling of the retinal pigment epithelium (RPE) to dark, patchy areas, and are most prominent in the posterior pole.
Congenital glaucoma (in 10% of cases)
Microphthalmos (occurs in 10% of cases)
Corneal edema in the absence of a raised IOP
Other TORCH infections
Others (syphilis, HIV, West Nile virus, varicella zoster, Epstein-Barr virus)
Herpes simplex virus
The serum of an infant is tested for rubella-specific IgM. Older infants may need additional investigations such as IgG avidity test, RT-PCR for demonstration of virus in lens matter and other body fluids such as serum, throat secretions, and urine.
The treatment is directed to the affected organs and tissues. If a cataract is present, lens aspiration is performed in conjunction with primary posterior capsulorrhexis and anterior vitrectomy. Intraocular lenses (IOLs) are usually avoided in young children. A severe inflammatory response can follow cataract surgery and requires intensive therapy with topical steroids with or without systemic steroids. Glaucoma is initially managed medically followed by glaucoma surgery if needed.
Poor when multiple systems are involved, and these children need a multidisciplinary team of a pediatrician, neurologist, ophthalmologist, otolaryngologist, and rehabilitation personnel.
Vijayalakshmi P, Rajasundari TA, Prasad NM, et al. Prevalence of eye signs in congenital rubella syndrome in South India: a role for population screening. Br J Ophthalmol. 2007;91(11):1467–1470.
Vijayalakshmi P, Srivastava KK, Poornima B, et al. Visual outcome of cataract surgery in children with congenital rubella syndrome. J AAPOS. 2003;7(2):91–95.
Vijaylakshmi P, Muthukkaruppan VR, Rajasundari A, et al. Evaluation of a commercial rubella IgM assay for use on oral fluid samples for diagnosis and surveillance of congenital rubella syndrome and postnatal rubella. J Clin Virol. 2006;37(4):265–268.
WEST NILE VIRUS
Sunir J. Garg and Moncef Khairallah
West Nile virus is a single-stranded RNA virus transmitted by mosquitoes. It causes a bilateral uveitis, with multifocal chorioretinal lesions that have a target-shaped and/or linear appearance.
Etiology and Epidemiology
West Nile virus was first identified in Uganda, and is endemic to many parts of the world.
Although birds are the natural host of the virus, the virus is transmitted by mosquitoes. West Nile virus is in the same virus family as yellow fever, dengue fever, and Japanese encephalitis.
Patients older than 50 years and those with diabetes may be more susceptible to ocular manifestations.
Only 20% of infected people have systemic symptoms such as fever, headache, nausea and vomiting, malaise, myalgias, joint pain, vertigo, confusion, aphasia and ataxia, lymphadenopathy, and skin rashes.
Less than 1% of infected people develop severe CNS symptoms, including mental status changes, sensory and motor neuropathies, and encephalitis.
Patients with ocular involvement get blurry vision, floaters, photophobia, and peripheral field loss.
Signs (Figs. 9-17 to 9-19)
Patients have bilateral ocular involvement.
The most characteristic finding is multiple, discrete, circular cream-colored lesions scattered throughout the mid-periphery, periphery, and posterior pole that become pigmented and “punched out” over time.
In diabetic patients, these chorioretinal lesions are more prevalent in the posterior pole, and tend to be larger and more numerous.
Linear clustering of chorioretinal lesions, following the course of the retinal nerve fiber layer, is a common finding.
Transient mild anterior chamber cells
Retinal arteriolar narrowing and/or occlusion, vascular sheathing
Optic disk edema and optic atrophy
Patients may develop choroidal neovascular membranes late in the course of the disease
Systemic lupus erythematosus
Rift Valley fever
Clinical exam is the most helpful.
Fluorescein angiography (FA) can demonstrate the chorioretinal lesions. In early stages of infection, the angiogram can shows early blockage with late staining. Chronic lesions will show “target-shaped” focal areas of hypofluorescence surrounded by hyperfluorescence.
Indocyanine green angiography (ICGA) shows more lesions in the form of hypofluorescent spots that those appreciated clinically or by fluorescein angiography.
Visual field testing can show nonspecific field defects.
MRI can demonstrate myelitis (a nonspecific sign).
IgM and IgG can be elevated, both in the serum and in cerebrospinal fluid.
Supportive, as this is a self-limited disease
Topical steroids can be used to treat anterior segment inflammation.
Generally good, with most patients retaining good central acuity.
Patients with more significant vascular occlusion can experience significant vision loss to the 20/400 range.
Chan CK, Limstrom SA, Tarasewicz DG, et al. Ocular features of West Nile virus infection in North America: a study of 14 eyes. Ophthalmology. 2006;113:1539–1546.
Khairallah M, Ben Yahia S, Attia S, et al. Linear pattern of West Nile virus-associated chorioretinitis is related to retinal nerve fibres organization. Eye (Lond). 2007; 21(7):952–955.
Khairallah M, Ben Yahia S, Ladjimi A, et al. Chorioretinal involvement in patients in patients with West Nile virus infections. Ophthalmology. 2004;111(11):2065–2070.
Khairallah M, Yahia SB, Letaief M, et al. A prospective evaluation of factors associated with chorioretinitis in patients with West Nile virus infection. Ocul Immunol Inflamm. 2007;15(6):435–439.
S. Lalitha Prajna and S. R. Rathinam
Chikungunya is a self-limited viral illness characterized by fever, fatigue, rash, arthralgias, and myalgias. However, more recent outbreaks have been associated with sight, as well as life-threatening complications.
Etiology and Epidemiology
It is an arthropod-borne, single-stranded RNA alphavirus, belonging to the family Togaviridae and it is transmitted by the bite of the mosquito Aedes aegyptei.
It is endemic in parts of Africa and Asia. Major epidemic outbreaks occurred in 2005.
Acute fever, chills, headache, fatigue, nausea, vomiting, myalgias, and a diffuse maculopapular rash.
Polyarticular and migratory joint pains
Photophobia, red eye, blurred vision, floaters, and retro-orbital pain
Loss of vision, color vision deficits, central or centrocecal scotoma, and peripheral field defects.
Signs (Figs. 9-20 to 9-22)
Mild granulomatous or nongranulomatous anterior uveitis
Pigmented, diffuse keratic precipitates either over the central or the entire corneal endothelium, and stromal edema.
Chikungunya retinitis. This can be differentiated from herpetic retinitis as Chikungunya retinitis has markedly less vitreous reaction and typically has posterior pole involvement, whereas herpetic retinitis in immunocompetent individuals has significant vitritis and multiple, focal lesions of retinitis in the retinal periphery.
Optic neuritis, neuroretinitis, and retrobulbar neuritis.
Herpetic viral retinitis
Virus isolation and RT-PCR are useful during the initial viremic phase, whereas serologies (IgM antibody) are useful after 10 days of infection.
Treatment is mainly supportive and includes rest, hydration, nonsteroidal anti-inflammatory agents, acetaminophen (paracetamol), and corticosteroids for refractory arthritis. Chloroquine has also been used to treat the joint pain.
Topical steroid eye drops for anterior uveitis.
IV/oral acyclovir and oral prednisone may be used to treat confluent retinitis. However, the efficacy of acyclovir against this virus has not yet been established.
The visual prognosis is good in cases of anterior uveitis, but may be poor in cases of posterior segment involvement.
Lalitha P, Rathinam S, Banushree K, et al. Ocular involvement associated with an epidemic outbreak of chikungunya virus infection. Am J Ophthalmol. 2007;144(4):552–556.
Mahendradas P, Ranganna SK, Shetty R, et al. Ocular manifestations associated with chikungunya. Ophthalmology. 2008;115(2):287–291.
Julie Gueudry, Bahram Bodaghi, and Phuc LeHoang
Syphilis is a sexually transmitted disease. It has been called “the great masquerader” due to its ability, particularly in the tertiary stage, to mimic numerous types of uveitis. Ocular syphilis is an uncommon but diagnostically important manifestation of the disease and it can result in major complications without appropriate treatment.
Etiology and Epidemiology
Syphilis is caused by the spirochete Treponema pallidum.
It is transmitted almost exclusively by sexual contact.
There have been recent syphilis outbreaks, especially in patients with AIDS. Patients with HIV are more likely to contract syphilis, and may have more rapid disease progression.
Approximately 84% of cases occur in males.
Ocular findings can occur in primary, secondary, latent, and tertiary syphilis.
Pain, redness, photophobia
Decreased vision, floaters
Skin changes and mucous membrane lesions
Signs (Figs. 9-23 to 9-29)
Manifestations are limited to chancre of the eyelid and the conjunctiva.
Secondary syphilis (unilateral or bilateral)
Cutaneous rash of the eyelids and blepharitis are common, as is anterior uveitis.
Conjunctivitis mimicking trachoma has been reported.
Dacryocystitis and dacryoadenitis are less common.
Keratitis, episcleritis, and scleritis have been described.
Chorioretinitis, neuroretinitis, papillitis, exudative retinal detachment, vasculitis, and acute posterior placoid chorioretinopathy occur later during the secondary stage.
Tertiary syphilis (unilateral or bilateral)
In addition to the other signs seen in secondary disease, gummas of the eyelid, interstitial keratitis, pseudo-retinitis pigmentosa, optic atrophy, and Argyll Robertson pupil can be seen.
Argyll Robertson pupils are bilateral small pupils that do not constrict when exposed to light, but do constrict when the eye accommodates.
If the patient has HIV, the syphilis manifests itself differently. They can get yellow, placoid, subretinal lesions (acute syphilitic posterior placoid chorioretinopathy). They can also just have vitritis.
Primary syphilis occurs 2 weeks to 2 months after inoculation.
The chancre (a painless ulcer) begins at the inoculation site, and may have associated regional lymphadenopathy.
Secondary syphilis occurs 1 to 3 months after untreated primary syphilis.
A maculopapular or pustular cutaneous rash, often on the trunk, palms, and soles, commonly occurs.
Mucous membrane lesions and generalized lymphadenopathy are also fairly common.
Acute syphilitic meningitis is a less common finding.
No clinical manifestations
Tertiary syphilis occurs months to years after untreated secondary syphilis.
Benign tertiary syphilis with gummas of the skin and bone can occur.
Cardiovascular involvement (aortitis, aortic valve insufficiency, and cardiovascular aneurysms) cause significant morbidity and mortality.
Neurosyphilis occurs in 5% to 10% of patients, and includes meningitis, headaches, sensorimotor loss, cranial nerve palsies, and seizures.
Congenital syphilis is rare and results from transplacental transmission. Only 60% of infected fetuses become newborns.
Systemic manifestations include rhinitis within the first few months of birth, and a maculopapular rash. Late findings include notched incisors (Hutchinson’s teeth), saddle-nose deformity, and sensorineural hearing loss.
It can present with various ocular findings, including:
Bilateral interstitial keratitis
Acute or chronic uveitis
Salt and pepper chorioretinitis
As syphilis can look like all forms of ocular inflammation, it should be considered in all kinds of uveitis.
Laboratory tests should include both nontreponemal and treponemal tests.
The nontreponemal tests, Venereal Disease Research Laboratory (VDRL) and rapid plasmin reagin (RPR) are nonspecific for Treponema pallidum, so false-positive are possible. These tests are also used to assess treatment response.
The main treponemal test is fluorescent Treponema antibody–absorption (FTA-Abs). It is specific for Treponema pallidum, so false-positive results are less common, but may still occur during pregnancy and in patients with autoimmune disorders. Once infected, patients will be positive for life.
HIV serology should be obtained as coinfection is possible.
Dark field microscopy, electron microscopy, and immunofluorescence can also be used.
Lumbar puncture should be considered to exclude asymptomatic neurosyphilis.
Patients with ocular syphilis should have CSF evaluation for VDRL titers, total protein, and cell counts.
Uveitis should be considered to be a manifestation of neurosyphilis and treated accordingly, even though this point remains controversial.
The recommended treatment for neurosyphilis is penicillin G sodium (18 to 24 million units IV daily) or penicillin G procaine (2.4 million units IM daily) plus probenecid PO for 10 to 14 days.
Ceftriaxone (2 g/day IV or IM for 10 to 14 days) may be considered in penicillin-allergic patients. However, cross-sensitivity exists and this agent has not been tested for the management of neurosyphilis. Some authors recommend penicillin desensitization for these patients prior to starting the cephalosporin.
Cycloplegics and topical corticosteroids may be useful if anterior segment inflammation is present, but they should be considered solely an adjunct to antibiotic therapy.
Patients should be monitored for a Jarisch-Herxheimer reaction, which occurs most often in secondary syphilis treated with penicillin (prophylaxis with corticosteroids may help in some cases).
Patients should also be evaluated and treated for other sexually transmitted diseases, including HIV, gonorrhea, and chlamydia. In the United States, patients with sexually transmitted diseases should be reported to the local Board of Health.
If patients receive prompt therapy, the prognosis is usually good with full visual recovery.
Retinitis may resolve without scarring within a few days after initiation of specific antibiotics.
If untreated, chronic progressive intraocular inflammation and complications may occur.
Aldave AJ, King JA, Cunningham ET Jr. Ocular syphilis. Curr Opin Ophthalmol. 2001;12(6):433–441.
Chao JR, Khurana RN, Fawzi AA, et al. Syphilis: reemergence of an old adversary. Ophthalmology. 2006;113(11):2074–2079.
Tran TH, Cassoux N, Bodaghi B, et al. Syphilitic uveitis in patients infected with human immunodeficiency virus. Graefes Arch Clin Exp Ophthalmol. 2005;243(9):863–869.
Sunir J. Garg
Lyme disease is a multisystem disease that can cause eye, skin, joint, heart, and neurologic problems.
Etiology and Epidemiology
It is caused by a spirochete, Borrelia burgdorferi, which is transmitted by the Ixodes deer tick.
In the United States, tick-endemic areas are along the Northeast Coast, the upper Midwest, and in northern California and Oregon.
Lyme disease has also been reported in Europe, Australia, China, and Japan.
Infected people will often have a history of camping or hiking.
These patients can develop essentially all types of ocular inflammation, ranging from a mild conjunctivitis in the early stages, to retinal vasculitis and optic neuropathy. They can also develop cranial neuropathies.
Early in the disease course, patients get flu-like symptoms, but they can develop significant arthritis, cardiac problems, headaches, and changes in mental status.
Approximately 50% of patients will recall being bitten by a tick.
Signs (Figs. 9-30 to 9-33)
Lyme disease is divided into three stages:
Stage 1: Patients have flu-like symptoms, including fevers, myalgias, and arthralgias, often with regional lymphadenopathy. Three-fourths of patients will have erythema chronicum migrans. It starts as a red papule that enlarges to form a ring or target-shaped rash. If untreated, these lesions often grow to several centimeters to nearly a meter in size, and then fade over the course of 3 to 4 weeks. Although it occurs in up to two-thirds of patients, many people may not recall having this sign. Early eye findings include conjunctivitis and episcleritis. In Europe, patients are infected with Borrelia afzelii, which can cause a lymphocytoma (of the earlobe or areola) and acrodermatitis chronica atrophicans (a violaceous area of atrophy followed by fibrosis on the dorsal aspect of the hands and feet).
Stage 2: This stage occurs 2 to 3 weeks to several years after infection. Patients may develop cardiac conduction defects (heart block), followed later by severe arthritis. Neurologically, they can get severe headaches, meningitis, and peripheral and cranial neuropathies, including a seventh nerve palsy. The ocular signs include conjunctivitis, keratitis, iridocyclitis, intermediate uveitis, vitritis, choroiditis, vasculitis, serous retinal detachments, and optic neuritis. They may also have diplopia from a third, fourth, fifth, or sixth nerve palsy, and may develop orbital myositis.
Stage 3: These patients have prolonged arthritis and encephalitis. As a result, they can have chronic fatigue and can develop ataxia and dementia. Although they can develop any of the eye findings listed above, bilateral keratitis is the most common manifestation.
Syphilis: If one cannot remember what Lyme does, it is a spirochete like syphilis, and has similar manifestations.
Lab tests for Lyme disease are good, but they are most helpful when combined with a high clinical suspicion.
Antibodies to Lyme disease are present for several weeks after infection. ELISA testing (followed by a Western blot) is useful. False negatives are common, both in the early stage of the disease and after treatment with antibiotics. False positives also occur, especially if the patient has had syphilis. (Because Lyme disease and syphilis are both spirochetes, there is some cross-reactivity with the tests, so one should order both syphilis and Lyme titers).
In Lyme endemic areas, 10% to 15% of patients may be antibody positive. If so, positive serology along with erythema chronicum migrans or one of the classic manifestations of Lyme disease makes the diagnosis. If not an endemic area, the patient should have two or more of the classic symptoms before the diagnosis is made.
Cerebrospinal fluid may show pleocytosis, but it is frequently unremarkable.
Antibiotics: For very early stage disease, treatment with oral amoxicillin, doxycycline, or erythromycin may be considered. For later stages, consider IV penicillin or ceftriaxone, and patients may need long-term treatment. If the patient has a penicillin allergy, use doxycycline.
Approximately one-fourth to one-third of patients with untreated erythema chronicum migrans will develop stage 2 disease. Less than 10% of these patients will develop chronic arthritis or neurologic disease. Once severe arthritis or neurologic symptoms occur, the symptoms persist despite antibiotic therapy.
Mikkilä HO, Seppälä IJ, Viljanen MK, et al. The expanding clinical spectrum of ocular lyme borreliosis. Ophthalmology. 2000;107(3):581–587.
Stanek G, Strle F. Lyme borreliosis. Lancet. 2003;362:1639–1647.
Stanek G, Strle F. Lyme borreliosis: a European perspective on diagnosis and clinical management. Curr Opin Infect Dis. 2009;22(5):450–454.